Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss – Yahoo Finance

by

  1. Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss Yahoo Finance
  2. Frequency falters after phase 2 fail, axing 2 assets and 55% of staff FierceBiotech
  3. Biotech layoffs 2023: Frequency Therapeutics to lay off most of its staff in wake of trial failure – Boston Business Journal The Business Journals
  4. Frequency stock crashes 75% on cutting hearing loss programs as trial fails; cuts 55% jobs Seeking Alpha
  5. Frequency Therapeutics President, CEO Lucchino Takes Medical Leave >FREQ MarketWatch
  6. View Full Coverage on Google News

Read original article here

Leave a Comment